/ Research Experience

2009 - The Risk of skin cancer development in Inflammatory Bowel Disease Patients on Azathioprine/6-Mercaptopurine

2009 - Psycho-sexual function, Fertility and Sperm Integrity in Men with IBD.

2008 - A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicentre Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative Colitis. Protocol C13006

2008 - A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of MLN0002 in Patients with Ulcerative Colitis and Crohn’s Disease. Protocol C13008

2008 - A Phase III, randomised, multi-centre, double-blind, parallel group, active comparator study to compare the efficacy and safety of SPD476 (mesalazine) 2.4g/day once daily (QD) with Asacol® 1.6g/day twice daily (BID) in the maintenance of remission in patients with ulcerative colitis. Protocol SPD476-304

2008 - Study Title: A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence of Diverticulitis. Protocol number: SPD476-313

2008 - A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Moderately to Severely Active Ulcerative Colitis. Protocol No. M06-827

2008 - A 5-Year, Registry Study of HUMIRA® (Adalimumab) in Patients With Moderately to Severely Active Crohn’s Disease (CD). Protocol No.: P06-134

2008 - A phase IIIb, multinational, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn's disease. Protocol No.: C87085

2008 - A phase IIIb, multinational, open-label, follow-on trial to C87085 designed to assess the long-term safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti TNF alpha monoclonal antibody, administered at weeks 0, 2 and 4, and then every 4 weeks thereafter, in subjects with moderately to severely active Crohn’s disease who have participated in study C87085. Protocol No: C87088

2007 - A Phase lll, Multicentre, Randomised, Placebo-Controlled, Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Crohn’s Disease (CD) Who Have Had Inadequate Clinical Response and/or Intolerance to Medical Therapy. Protocol No.IM101-084

2007 - A Phase lll, Multicentre, Randomised, Placebo-Controlled, Withdrawal Study to Evaluate the Clinical Efficacy and Safety of Maintenance Therapy with Abatacept in Subjects with Active Ulcerative Colitis (UC) Who Have Had Inadequate Clinical Response and/or Intolerance to Medical Therapy. Protocol No.IM101-108

2005 - Protocol CDP870-034: A Phase III multi-national, multi-centre, open label, 52 week safety study to assess the safety of re-exposure after a variable interval and subsequent chronic therapy with humanised anti-TNF PEG conjugated CDP870 400mg sc, (dosed at weeks 0,2 and 4 then 4-weekly to Week 48), in the treatment of patients with active Crohn’s disease who have previously been withdrawn from studies CDP870-031 or CDP870-032 due to an exacerbation of Crohn’s disease.